Revolution Medicines, Inc. (RVMD)
After hours:
| Previous Close | 35.33 |
| Open | 35.38 |
| Bid | 35.91 x 400 |
| Ask | 35.99 x 800 |
| Day's Range | 34.65 - 36.36 |
| 52 Week Range | 15.44 - 38.73 |
| Volume | |
| Avg. Volume | 1,464,711 |
| Market Cap | 5.922B |
| Beta (5Y Monthly) | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.86 |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41.58 |
GlobeNewswireRevolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology" Session at AACR 2024 in San DiegoREDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer-reviewed research p
- GlobeNewswire
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in preclinical models of RAS-mutant pancreatic ductal adenocarcinoma (PDAC) First paper demonstrates RMC-7977 successfully targets signaling by both mutant and wild-type forms of RAS to drive potent and durable inhibition of RAS-mutated cancers Second paper highlights translation-focused research with RMC
- GlobeNewswire
Revolution Medicines to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum. Details of the company’s participation are as follows: 23rd Annual Needham
